Global Search | Novartis

Hide Filters

Showing 2804 results

Press release / May 17, 2017

Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities

Better Hearts Better Cities is a Novartis Foundation initiative to improve cardiovascular health in low-income urban communities by addressing the prevention, management and control of hypertension…
Press release / May 23, 2017

Novartis' new analyses reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroids

New analyses from the FLAME study suggest dual bronchodilator Ultibro® Breezhaler® provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil (a type of…
Press release / May 19, 2017

Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)

Phase III trial, first-line treatment with Zykadia resulted in improved progression-free survival (PFS) over SOC chemotherapy with maintenance, including in patients with brain metastases[1]…
Press release / May 30, 2017

Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients

Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months.CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the…
Press release / May 26, 2017

Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)

In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared to 8.1 months with chemotherapy[1] The overall intracranial response rate…
Press release / Sep 28, 2015

Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®

Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist Tafinlar + Mekinist combination also demonstrated…
Press release / Sep 30, 2015

Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis

In the FUTURE 1 study, secukinumab showed rapid and significant efficacy in active psoriatic arthritis (PsA) patients, including improvement of skin and joint disease and reduction in progression of…
Press release / Oct 02, 2015

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

Etanercept is an anti-TNF medicine used to treat a range of immunological diseases including rheumatoid arthritis and psoriasis. Sandoz is seeking approval for all indications included in the…
Press release / Oct 08, 2015

Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years

NEDA-4 - no evidence of disease activity based on four parameters - relapses, MRI lesions, brain shrinkage and disability progression - is a comprehensive measure of MS disease control 31.2%…
Press release / Oct 05, 2015

Alcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery

AcrySof® IQ Aspheric Intraocular Lens (IOL) with UltraSertTM Pre-loaded Delivery System helps maintain integrity of incision while facilitating smooth IOL delivery Follows earlier FDA approval…